Canaccord analyst Kyle Mikson lowered the firm’s price target on Tempus AI (TEM) to $80 from $95 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Balanced Outlook on Tempus AI: Evaluating Data Business Expansion and Personalized Medicine Potential
- Tempus AI price target lowered to $80 from $90 at BofA
- Tempus AI price target lowered to $80 from $85 at JPMorgan
- Tempus AI, Inc. Class A: Balancing Potential Leadership in AI-Driven Healthcare with Cautious Hold Rating
- Tempus AI assumed with an Overweight at Morgan Stanley